Signaling pathway mediating myeloma cell growth and survival

T Hideshima, KC Anderson - Cancers, 2021 - mdpi.com
Simple Summary The bone marrow (BM) microenvironment plays a crucial role in
pathogenesis of multiple myeloma (MM), and delineation of the intracellular signaling …

The importance of Ras in drug resistance in cancer

FM Healy, IA Prior, DJ MacEwan - British journal of …, 2022 - Wiley Online Library
In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug
resistance and the progress made in the abrogation of this resistance, through …

Optical genome mapping reveals the complex genetic landscape of myeloma

A Giguère, I Raymond-Bouchard, V Collin, JS Claveau… - Cancers, 2023 - mdpi.com
Simple Summary Myeloma is a hematological cancer characterized by numerous genetic
abnormalities currently identified using fluorescent in situ hybridization (FISH). However …

Pathogenesis and treatment of multiple myeloma

P Yang, Y Qu, M Wang, B Chu, W Chen, Y Zheng… - MedComm, 2022 - Wiley Online Library
Multiple myeloma (MM) is the second‐ranking malignancy in hematological tumors. The
pathogenesis of MM is complex with high heterogeneity, and the development of the …

KRAS and RAS-MAPK pathway deregulation in mature B cell lymphoproliferative disorders

E Vendramini, R Bomben, F Pozzo, T Bittolo, E Tissino… - Cancers, 2022 - mdpi.com
Simple Summary KRAS and genes in the RAS-MAPK pathway are among the most
frequently deregulated genes in solid tumors and in this context a large amount of KRAS …

[HTML][HTML] Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

X Mo, Q Niu, AA Ivanov, YH Tsang, C Tang, C Shu, Q Li… - Cell, 2022 - cell.com
Comprehensive sequencing of patient tumors reveals genomic mutations across tumor
types that enable tumorigenesis and progression. A subset of oncogenic driver mutations …

Where we stand with precision therapeutics in myeloma: prosperity, promises, and pipedreams

D Pan, J Richter - Frontiers in Oncology, 2022 - frontiersin.org
Multiple myeloma remains an incurable disease despite numerous novel agents being
approved in the last decade. Furthermore, disease behavior and susceptibility to current …

LMP2 and TAP2 impair tumor growth and metastasis by inhibiting Wnt/β-catenin signaling pathway and EMT in cervical cancer

Z Cheng, H Wang, Z Yang, J Li, X Chen - BMC cancer, 2023 - Springer
Background The roles of low molecular mass polypeptide 2 (LMP2) and transporter-
associated with antigen processing (TAP2) in tumorigenesis are controversial. Here we …

[HTML][HTML] The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

M Sellin, S Berg, P Hagen, J Zhang - Translational Oncology, 2022 - Elsevier
Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of
immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however …

Targeting reactive oxygen species metabolism to induce myeloma cell death

M Caillot, H Dakik, F Mazurier, B Sola - Cancers, 2021 - mdpi.com
Simple Summary Multiple myeloma (MM) is a neoplastic disease of plasma cells,
characterized by a complex array of clinical manifestations. Despite extensive efforts and …